Ultragenyx Pharmaceutical Inc.RAREReports Tue, Nov 3 · Third Quarter 2026
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · United States · ultragenyx.com
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. It has built a portfolio of approved therapies and product candidates aimed at diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
Key ratios
FCF / Sales
-68.2%TTM
2025
-70.1%2024
-75.2%2023
-119.6%
Net margin
-81.7%TTM
2025
-85.4%2024
-101.6%2023
-139.9%
ROA
-24.2%TTM
2025
-22.0%2024
-22.4%2023
-23.4%
ROE
-608.5%TTM
2025
-608.5%2024
-211.8%2023
-193.3%
Revenue growth
17.5%TTM
2025
20.2%2024
29.0%2023
19.5%
Recent news
Ultragenyx to Host Conference Call for Third Quarter 2026 Financial Results and Corporate Update
Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $203 Million
Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million
Ultragenyx Announces Phase 3 Aspire Results in Angelman Syndrome
Track RARE in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer